Table 2.
Patient Characteristics
| Patient Demographics | |
|---|---|
| Gender: male, n (%) | 25 (78.1) |
| Age at LVAD implantation, mean ± SE | 61.2 ± 1.2 |
| Body mass index, mean ± SE | 30.4 ± 0.91 |
| Race, n (%) | |
| Caucasian | 16 (50.0) |
| African American | 16 (50.0) |
| Past medical history, n (%) | |
| Hypertension | 26 (81.3) |
| Ischemic etiology | 23 (71.9) |
| Atrial fibrillation | 21 (65.6) |
| History of ventricular tachycardia | 21 (65.6) |
| Diabetes mellitus | 18 (56.3) |
| History of prior bleeding events | 13 (40.6) |
| History of prior thrombotic events | 9 (28.1) |
| Current infection | 3 (9.4) |
| LVAD, n (%) | |
| Heartmate II | 15 (46.9) |
| HVAD | 13 (40.7) |
| Heartmate III | 4 (12.4) |
| CF-LVAD rotations per minute, mean ± SE | |
| Heartmate II | 9,211.3 ± 105.9 |
| HVAD | 2,821.5 ± 61.0 |
| Heartmate III | 5,550.0 ± 236.3 |
| Destination therapy, n (%) | 17 (53.1) |
| INR at the time of the bleed before LAR, mean ± SE | 2.2 ± 0.094 |
| Aspirin, n (%) | |
| None | 8 (25.0) |
| 81 mg | 9 (28.1) |
| 162 mg | 1 (3.1) |
| 325 mg | 14 (43.8) |
| Angiotensin-converting enzyme inhibitor/angiotensin II receptor antagonist use, n (%) | 19 (59.4) |
| Digoxin use, n (%) | 4 (12.5) |
| Acid suppression therapy, n (%) | |
| Proton pump inhibitor | 30 (93.8) |
| Histamine-2 receptor antagonist | 2 (6.2) |
CF-LVAD, continuous-flow left ventricular assist device; HMII; HVAD; LAR, long-acting release.